Physician profile
Lesly Davidson
NPI 1861433997
$6,213.99
in general payments reported to CMS, 2019-2025
31 companies · $437 in 2025
The $437 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $841 · 2021: $1,062 · 2022: $677 · 2023: $958 · 2024: $1,087 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.82 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,300.01 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Merz North America, INC. | $825.64 | 2019-2023 | Xeomin |
| Janssen Biotech, INC. | $548.62 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $489.54 | 2019-2024 | Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $331.74 | 2019-2024 | Aklief, Oracea, Twyneo |
| Amgen INC. | $271.95 | 2019-2025 | Otezla |
| Almirall LLC | $251.20 | 2021-2025 | Klisyri |
| Leo Pharma INC. | $245.57 | 2019-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $235.08 | 2019-2025 | |
| Pfizer INC. | $213.32 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $195.98 | 2019-2025 | |
| Incyte Corporation | $170.05 | 2021-2024 | Opzelura |
| Genzyme Corporation | $157.70 | 2021-2024 | |
| Ucb, INC. | $134.88 | 2019-2024 | Bimzelx |
| Dermavant Sciences, INC. | $124.13 | 2023-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $123.99 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $100.50 | 2021 | |
| Lilly USA, LLC | $80.78 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $53.61 | 2023-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $53.14 | 2019 | |
| Allergan, INC. | $45.54 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.30 | 2019 | |
| Organon LLC | $37.97 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $32.69 | 2022-2023 | Sotyktu |
| Mission Pharmacal Company | $31.28 | 2020-2021 | |
| Botanix Sb INC | $25.59 | 2025 | Sofdra |
| Journey Medical Corporation | $23.24 | 2022 | |
| Epi Health, LLC | $22.57 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.01 | 2019 | |
| Dermira, INC. | $17.40 | 2020 | |
| Merck Sharp & Dohme LLC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesly Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.